Business Context and Reporting Period
Company: Evogene Ltd.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2014
Accounting Standards: International Financial Reporting Standards (IFRS)
Business Overview: Evogene is an Israeli plant genomics company that uses computational technologies to identify genes for improving seed traits (yield, abiotic/biotic stress) and developing ag-chemicals. The company operates primarily through strategic collaborations with major agricultural firms (e.g., Monsanto, Bayer) and maintains a wholly-owned subsidiary, Evofuel, focused on developing castor bean seeds for biofuel feedstock. The company is in a pre-revenue stage regarding royalties and castor seed sales, currently generating revenue from research and development (R&D) payments and share purchase arrangements.
Key Financial Metrics (Year Ended Dec 31, 2014)
| Metric | 2014 (in thousands) | 2013 (in thousands) |
|---|---|---|
| Total Revenue | $14,511 | $17,581 |
| Cost of Revenues | $9,709 | $10,114 |
| Gross Profit | $4,802 | $7,467 |
| Operating Loss | $(15,256) | $(8,721) |
| Net Loss | $(14,530) | $(8,878) |
| Basic Net Loss Per Share | $(0.58) | $(0.45) |
| Cash and Cash Equivalents | $5,213 | $95,454 |
| Marketable Securities | $80,040 | $31,452 |
| Short-term Bank Deposits | $30,046 | $0 |
| Total Current Assets | $118,371 | $129,552 |
| Total Liabilities | $11,504 | $12,564 |
| Working Capital | $110,452 | $120,978 |
| Shareholders' Equity | $116,082 | $124,747 |
Note: The company reported no debt other than liabilities related to government grants and operating payables. Financing income was $2.2 million, primarily from interest on marketable securities.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 17.5% ($3.1 million) to $14.5 million. This was primarily driven by an 87.7% drop in "share purchase related revenues" (from $2.6 million to $0.3 million) due to the accounting treatment of a prior agreement amendment with Monsanto. R&D payments decreased slightly by 5.5%.
- Widening Losses: Operating loss increased by 75% to $15.3 million. This was caused by the revenue decline combined with a 26.2% increase in R&D expenses ($14.0 million) due to expanded self-funded activities in insect resistance, ag-chemicals, and Evofuel.
- Liquidity Shift: While cash and cash equivalents dropped significantly from $95.5 million to $5.2 million, the company increased its holdings in marketable securities (from $31.5 million to $80.0 million) and short-term bank deposits ($30.0 million). Total liquid assets remained robust at approximately $115 million.
- Segment Performance: The Evogene segment (seed traits/ag-chemicals) generated all revenue ($14.5 million) but recorded an operating loss of $13.1 million. The Evofuel segment (castor seeds) remained pre-revenue with an operating loss of $2.2 million.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy
- Commercialization Timeline: The company expects to begin earning royalties from seed traits in at least six years. Evofuel expects to launch castor bean varieties in Brazil in 2016.
- Expansion: In February 2015, the company announced plans to establish a U.S. R&D facility in St. Louis, Missouri, to focus on insect resistance validation.
- Self-Funding: Management intends to selectively self-fund a larger portion of initial R&D costs to capture a larger share of future collaborator revenues.
Risk Factors
- Collaborator Concentration: Monsanto and Bayer accounted for 87% of 2014 revenues. Termination of these agreements would have a material adverse effect.
- Development Uncertainty: Product development cycles are lengthy (6-13 years) and uncertain. There is no guarantee that traits will be commercialized or that regulatory approvals will be obtained.
- Commodity Prices: A decrease in commodity prices (e.g., corn) in 2014 may impact collaborators' R&D budgets and future payments to Evogene.
- Geopolitical Risk: Operations are based in Israel, exposing the company to regional security risks and potential military call-ups of employees.
- PFIC Status: The company believes it was not a Passive Foreign Investment Company (PFIC) in 2014 but notes that a significant decrease in market capitalization could trigger PFIC status, resulting in adverse tax consequences for U.S. shareholders.
Unusual Items
- Share Purchase Revenues: A significant portion of historical revenue was non-cash "share purchase related revenue" resulting from the accounting treatment of share purchases by Monsanto and Bayer at a premium. This revenue stream is volatile and decreased sharply in 2014.
Key Facts for Investor Verification
- Revenue Dependency: Verify the status and renewal terms of the collaboration agreements with Monsanto (expires 2016/2019) and Bayer (expires 2017), which drive the vast majority of cash flow.
- Cash Burn Rate: Assess the sustainability of the current cash position (~$115 million in liquid assets) against the increasing operating losses (up to $15.3 million in 2014) and planned capital expenditures for the U.S. facility and Evofuel expansion.
- R&D Milestones: Monitor progress on the 29 seed traits and ag-chemical products currently in development, specifically those moving from Discovery/Phase I to Phase II, as this triggers milestone payments.
- Evofuel Commercialization: Track the 2016 target for commercial launch of castor bean seeds in Brazil and the success of field trials in rain-fed conditions.
- Government Grants: Review the terms of Israeli government grants (OCS, BIRD) which provide funding but impose royalty obligations and restrictions on technology transfer outside Israel.